A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than ...
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results